Start here if you're new
what it is
Vertex sells cystic fibrosis drugs that print cash, then uses that cash to build new treatments in pain, kidney disease, and gene editing.
how it gets paid
Last year Vertex Pharm made $12.0B in revenue.
why it's growing
Revenue grew 8.9% last year. Annual revenue reached $12.0B, up 8.9%. Full-year EPS snapped back to $18.40 in 2025 from -$2.08 in 2024, which is a wild swing even by.
what just happened
Vertex closed 2025 with Q4 EPS of $5.03, above the $4.32 consensus estimate by 16.44%.
At a glance
A+ balance sheet — rock-solid finances — built to survive anything
5/100 earnings predictability — expect surprises
26.7x trailing p/e — priced about right
16.5% return on capital — nothing to write home about
xvary composite: 72/100 — average
What they do
Vertex sells cystic fibrosis drugs that print cash, then uses that cash to build new treatments in pain, kidney disease, and gene editing.
Vertex has spent 12 years building approved cystic fibrosis drugs, from Kalydeco in 2012 to Alyftrek in December 2024. That matters because doctors and patients already live inside this ecosystem, and the company still posts a 34.8% operating margin. Pipeline → future drug lineup → so what: your cash cow funds the next act without a weak balance sheet, backed by an A+ balance sheet grade.
How they make money
$12.0B
annual revenue · their business grew +8.9% last year
total revenue
$12.0B
+8.9%
The products that matter
CFTR modulator therapies
Cystic Fibrosis Franchise
$12.0B revenue
this suite of drugs generated $12.0B last year. right now, that is virtually the whole company. the quiet part: the core franchise is both the moat and the concentration risk.
core engine
gene-editing therapy launch
Casgevy
approved 2025
Casgevy matters because Vertex needs something beyond a $12.0B CF base. So far, it matters more to the thesis than to the reported mix.
next act
pain and kidney pipeline
Suzetrigine + renal programs
pipeline expansion
suzetrigine was approved in 2025, and the broader pipeline is the entire diversification case. it has to become big enough to matter against a $12.0B base.
prove it
Key numbers
$17B
2029 revenue
This is the growth target versus $12.0B today. Plain English: Vertex needs to add $5.0B of sales in four years.
16.5%
return on capital
Return on capital → how well management turns invested money into profit → so what: Vertex earns about $0.17 for every $1 invested.
34.8%
operating margin
Operating margin → profit after running the business → so what: Vertex keeps about $0.35 from each $1 of sales before interest and taxes.
26.7x
trailing P/E
P/E → price divided by earnings → so what: you are paying 26.7 years of trailing profit for one share at today's price.
Financial health
A+
strength
- balance sheet grade A+ — near the highest rating possible
- risk rank 2 — safer than 80% of stocks
- price stability 75 / 100
- net profit margin 37.6% — keeps 38 cents of every dollar in revenue
- return on equity 16% — $0.16 profit for every $1 investors have put in
A+ with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in VRTX 3 years ago → it's now worth $16,430.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
Vertex closed 2025 with Q4 EPS of $5.03, above the $4.32 consensus estimate by 16.44%.
Annual revenue reached $12.0B, up 8.9%. Full-year EPS snapped back to $18.40 in 2025 from -$2.08 in 2024, which is a wild swing even by biotech standards.
$3.3B
revenue
$5.03
eps
37.6%
gross margin
the number that mattered
The number that mattered was the 16.44% EPS beat, because it showed Vertex is still squeezing more profit out of a mature CF base.
-
vertex pharmaceuticals appears to be faring well, considering moderate growth from its newer drugs.
-
indeed, the biotech company closed 2025 with fourth-quarter revenues up 10%, vs. prior year, and adjusted share profit jumping 26%. (note that beginning with 2025, our presentation reflects adjusted earnings.) the core cystic fibrosis (or cf, a debilitating lung disease) franchise continued to benefit from solid demand for its newest addition alyftrek, a once-daily triple-drug treatment for cf patients 6 years and up, as well as from higher prices.
-
meanwhile, casgevy, a crispr gene-editing therapy for sickle cell disease (scd) and transfusion-dependent beta thalassemia (tdt), and journavx (suzetrigine), a non-opioid treatment for moderate-to-severe acute pain, contributed to sales, too, though slow adoption and competition tempered growth some since the drugs’ recent launch.
-
expanding the drug portfolio beyond cf remains a key part of the strategy.while efforts in recent years have been mostly aimed at deepening its lineup of cf medicines, vertex has been branching out to other therapeutic areas with high medical need. it expects to strengthen growth not only for its latest cf therapy, but for its newer non-cf drugs, expanding their global availability by gaining approvals, increasing patient adoption, and getting reimbursements in markets outside the u.s. moreover, several mid- and late-stage pipeline programs are advancing, which have good growth prospects, targeting kidney disease, type 1 diabetes, diabetic neuropathy, and muscular dystrophy. one notable standout is povetacicept, which is in multiple studies, and will undergo expedited fda review, with potential approval later this year for igan nephropathy (renal disease).
-
our overall view remains positive.we expect 2026 revenues to rise to around $13.0 billion, on par with management’s outlook, reflecting continued solid growth of the newer drugs.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Vertex's risk stack is unusually concentrated: virtually all of today's $12.0B revenue still traces back to one cystic fibrosis franchise, while the stock asks you to believe the next franchises are coming on time.
med
the business is still one franchise wearing several pipeline slides
the current page data points to virtually the full $12.0B revenue base coming from the CF franchise. that is a dream setup until competition or patent erosion enters the room.
impact: when exclusivity weakens, the revenue at risk is not a side business. it's the business.
med
the second act can stay strategically important and financially small
Casgevy, suzetrigine, and kidney programs matter because the stock is already valued at roughly $125B. if newer assets do not become financially meaningful, investors stop paying a premium for optionality and start valuing Vertex like a harvest story.
impact: at this size, scientific progress is not enough. you need revenue streams that visibly change a $12.0B base.
med
new launches have to clear a very high valuation bar
2026 revenue is expected around $13.0B. that is growth, but not explosive growth. if commercial ramps arrive slower than investors want, the stock does not have a lot of narrative slack at 26.7x earnings.
impact: a slower ramp hits sentiment first, then valuation.
med
margin drift would hit the quality premium fast
annual net margin is 38.8%, but the latest quarter printed 35.2%. one quarter is not a trend. two identities are still competing here: durable franchise compounder and pipeline story that needs spending.
impact: if margins live closer to 35.2% while growth stays modest, the stock starts looking expensive instead of elite.
the whole bear case fits in one sentence: if the CF engine keeps carrying almost all of the revenue while newer products stay small, you are paying a premium multiple for a business mix that has not actually diversified.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
2026 revenue versus $13.0B
the current outlook points to around $13.0B this year. if results drift below that, the stock loses some room to keep calling the pipeline a growth engine.
calendar
Casgevy adoption
this is the headline asset outside CF. you want commercial traction, not just scientific prestige.
trend
margin direction
annual net margin is 38.8%, while the last quarter printed 35.2%. if that gap keeps showing up, part of the quality premium fades.
risk
institutional selling streak
institutions were net sellers for 2 straight quarters. if that extends, big money is telling you patience with the diversification story is thinning.
Analyst rankings
short-term outlook
average
momentum score 3 — the stock is trading more or less with the broader market. in human-speak, analysts are not seeing a near-term breakout signal.
safety
better than most
stability score 2 — safer than roughly 80% of stocks. unusual for biotech, and a real advantage if pipeline timelines slip.
chart momentum
average
technical score 3 — no strong trend signal either way. the chart is not doing the storytelling right now.
earnings predictability
5 / 100
the score is low, which means quarterly outcomes can surprise you. the business is stable, but biotech timelines still introduce volatility.
source: institutional data
Institutional activity
institutions have been net selling for 2 consecutive quarters — 681 buyers vs. 747 sellers in 3q2025. total institutional holdings: 0.2B shares. net selling for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$397
$817
$491
current price
$607
target midpoint · +24% from current · 3-5yr high: $720 (+45% · 10% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive